Ultra-Low Power ASIC Enables Commercialization of Novel Implantable Continuous Glucose SensorPOCATELLO, Idaho--Nov. 7, 2005
--AMI Semiconductor (Nasdaq:AMIS), a designer and manufacturer of state-of-the-art integrated mixed-signal and structured digital products for the automotive, medical and industrial markets, today announced that DexCom Inc. (Nasdaq:DCXM), a leading manufacturer of implantable medical devices, is using an AMIS ultra-low power wireless ASIC system-on-chip (SoC) solution for a new implantable glucose monitoring system.
"This design win is proof that AMI Semiconductor's strategy of combining ultra-low power analog and mixed-signal expertise with our ASTRIC(TM) wireless technology that are quickly and easily adaptable to specific customer requirements is paying off," said Mike Rice, medical marketing & business development manager for AMIS. "We are providing our customers with the ability to achieve cutting-edge performance, integration and product differentiation in the shortest possible time frame."
"We carefully evaluated several vendors and selected AMIS because of their expertise in ultra-low power, mixed-signal ASIC design and their ability to prove feasibility in using RF in implantable applications," said Andy Rasdal, president and CEO of DexCom. "The performance of the AMIS solution is very impressive, considering the ultra-low power consumption requirements and other unique features of the device. AMI Semiconductor's knowledge and experience in the medical market helped make the process easier, and we look forward to working together in the future."
"The wireless frequency band used in this application is the 402-405MHz medical implant communication service (MICS) band, which is reserved for communication with implantable devices. Our ASTRIC technology with its quick start oscillator proved crucial to reach the very low power consumption allowed for the RF communication," said Kirk Peterson, AMIS wireless product manager.
The specifications for the AMIS solution were developed in close collaboration between the engineering teams at DexCom and AMIS and required extremely low power consumption due to implant longevity and size restrictions. The total average current drain from the battery is less than 3uA. The AMIS SoC includes a 32kHz oscillator, current and voltage references, high-precision analog-to-digital converter (ADC), digital filtering and sensor bias running at 100-percent duty cycle, and a low-duty RF section.
Additional information about the Dexcom's products can be found on the Dexcom Web page at: http://www.dexcom.com/sts.php
Representatives from AMIS will be attending the Diabetes Technology Conference, November 10-12, in San Francisco. For more information, please visit www.amis.com/applications/medical
and http://diabetestechnology.org/About AMI Semiconductor
AMI Semiconductor (AMIS) is a leader in the design and manufacture of silicon solutions for the real world. As a widely recognized innovator in state-of-the-art integrated mixed-signal and structured digital products, AMIS is committed to providing customers with the optimal value, quickest time-to-market semiconductor solutions. Offering unparalleled manufacturing flexibility and dedication to customer service, AMI Semiconductor operates globally with headquarters in Pocatello, Idaho, European corporate offices in Oudenaarde, Belgium, and a network of sales and design centers located in the key markets of North America, Europe and the Asia Pacific region. For more information please visit the AMIS Web site at www.amis.com
DexCom, Inc., headquartered in San Diego, Calif., is focused on developing technology for the continuous monitoring of glucose in people with diabetes. DexCom is committed to developing technologies and products that improve the lives of people with diabetes.